XML 41 R30.htm IDEA: XBRL DOCUMENT
v3.24.3

Segment Information (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2024
Segment Reporting [Abstract] |
Schedule of Segment Information | The following table summarizes segment information for the three and nine months ended September 30, 2024, and 2023 (in thousands):
|  | Three Months Ended September 30, |  | Nine Months Ended September 30,
|  | 2024 |  | 2023 |  | 2024 |  | 2023
Net revenues: |  |  |  |  |  |  |  |
Clinical Services |  | $ | 145,783 |  |  | $ | 127,553 |  |  | $ | 421,706 |  |  | $ | 365,578 |
Advanced Diagnostics |  | 22,041 |  |  | 24,401 |  |  | 66,860 |  |  | 70,513 |
Total revenue |  | 167,824 |  |  | 151,954 |  |  | 488,566 |  |  | 436,091 |
Cost of revenue: |  |  |  |  |  |  |  |
Clinical Services(1) |  | 80,058 |  |  | 73,994 |  |  | 234,996 |  |  | 213,032 |
Advanced Diagnostics(2) |  | 12,886 |  |  | 15,649 |  |  | 40,727 |  |  | 46,043 |
Total cost of revenue |  | 92,944 |  |  | 89,643 |  |  | 275,723 |  |  | 259,075 |
Gross Profit: |  |  |  |  |  |  |  |
Clinical Services |  | 65,725 |  |  | 53,559 |  |  | 186,710 |  |  | 152,546 |
Advanced Diagnostics |  | 9,155 |  |  | 8,752 |  |  | 26,133 |  |  | 24,470 |
Total gross profit |  | $ | 74,880 |  |  | $ | 62,311 |  |  | $ | 212,843 |  |  | $ | 177,016 |
(1) Clinical Services cost of revenue adjustments for the three months ended September 30, 2024 includes $4.3 million of amortization of acquired intangible assets and $0.2 million of stock-based compensation. Clinical Services cost of revenue adjustments for the three months ended September 30, 2023 includes $4.3 million of amortization of acquired intangible assets. Clinical Services cost of revenue adjustments for the nine months ended September 30, 2024 includes $13.0 million of amortization of acquired intangible assets and $0.7 million of stock-based compensation. Clinical Services cost of revenue adjustments for the nine months ended September 30, 2023 includes $12.8 million of amortization of acquired intangible assets. There were no stock-based compensation amounts recorded for the three and nine months ended September 30, 2023. (2) Advanced Diagnostics cost of revenue adjustments for the three months ended September 30, 2024 includes $0.6 million of amortization of acquired intangible assets and $0.1 million of stock-based compensation. Advanced Diagnostics cost of revenue adjustments for the three months ended September 30, 2023 includes $0.6 million of amortization of acquired intangible assets. Advanced Diagnostics cost of revenue adjustments for the nine months ended September 30, 2024 includes $1.8 million of amortization of acquired intangible assets and $0.3 million of stock-based compensation. Advanced Diagnostics cost of revenue adjustments for the nine months ended September 30, 2023 includes $1.8 million of amortization of acquired intangible assets. There were no stock-based compensation amounts recorded for the three and nine months ended September 30, 2023.

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration